More on RHHBY
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $49.07 |
|
|||
| Open | $48.86 | ||||
| 52 Wk High | $35.13 | ||||
| 52 Wk Low | $28.10 | ||||
| Day High | $49.28 | ||||
| Day Low | $48.83 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,914,382 | ||||
- U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer wit
- FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
- Genentech to present obesity drug data at diabetes conference
- Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
- Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026
- New Research Confirms Data Quality as the Defining Priority Across the Real-World Evidence Landscape
- Flatiron Health Launches Flatiron Telescope, a New AI Platform Delivering Oncology Insights in Minutes
- Genentech presents new giredestrant breast cancer data at ASCO 2026
- Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
- FDA approves Genentech's Tecentriq for bladder cancer with ctDNA guidance
Entities mentioned with RHHBY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Industrial Production | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
